Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis.
Caridha D, Vesely B, van Bocxlaer K, Arana B, Mowbray CE, Rafati S, Uliana S, Reguera R, Kreishman-Deitrick M, Sciotti R, Buffet P, Croft SL. Caridha D, et al. Among authors: reguera r. Int J Parasitol Drugs Drug Resist. 2019 Dec;11:106-117. doi: 10.1016/j.ijpddr.2019.06.003. Epub 2019 Jun 20. Int J Parasitol Drugs Drug Resist. 2019. PMID: 31320296 Free PMC article. Review.
Antileishmanial Effect of 1,5- and 1,8-Substituted Fused Naphthyridines.
Melcón-Fernandez E, Martín-Encinas E, Palacios F, Galli G, Reguera RM, Martínez-Valladares M, Balaña-Fouce R, Alonso C, Pérez-Pertejo Y. Melcón-Fernandez E, et al. Among authors: reguera rm. Molecules. 2023 Dec 22;29(1):74. doi: 10.3390/molecules29010074. Molecules. 2023. PMID: 38202656 Free PMC article.
Appraisal of a Leishmania major strain stably expressing mCherry fluorescent protein for both in vitro and in vivo studies of potential drugs and vaccine against cutaneous leishmaniasis.
Calvo-Álvarez E, Guerrero NA, Alvarez-Velilla R, Prada CF, Requena JM, Punzón C, Llamas MÁ, Arévalo FJ, Rivas L, Fresno M, Pérez-Pertejo Y, Balaña-Fouce R, Reguera RM. Calvo-Álvarez E, et al. Among authors: reguera rm. PLoS Negl Trop Dis. 2012;6(11):e1927. doi: 10.1371/journal.pntd.0001927. Epub 2012 Nov 29. PLoS Negl Trop Dis. 2012. PMID: 23209866 Free PMC article.
Walking a tightrope: drug discovery in visceral leishmaniasis.
Balaña-Fouce R, Pérez Pertejo MY, Domínguez-Asenjo B, Gutiérrez-Corbo C, Reguera RM. Balaña-Fouce R, et al. Among authors: reguera rm. Drug Discov Today. 2019 May;24(5):1209-1216. doi: 10.1016/j.drudis.2019.03.007. Epub 2019 Mar 12. Drug Discov Today. 2019. PMID: 30876846 Review.
Antileishmanial activity of terpenylquinones on Leishmania infantum and their effects on Leishmania topoisomerase IB.
Pérez-Pertejo Y, Escudero-Martínez JM, Reguera RM, Balaña-Fouce R, García PA, Jambrina PG, San Feliciano A, Castro MÁ. Pérez-Pertejo Y, et al. Among authors: reguera rm. Int J Parasitol Drugs Drug Resist. 2019 Dec;11:70-79. doi: 10.1016/j.ijpddr.2019.10.004. Epub 2019 Oct 22. Int J Parasitol Drugs Drug Resist. 2019. PMID: 31678841 Free PMC article.
Ex Vivo Phenotypic Screening of Two Small Repurposing Drug Collections Identifies Nifuratel as a Potential New Treatment against Visceral and Cutaneous Leishmaniasis.
Domínguez-Asenjo B, Gutiérrez-Corbo C, Álvarez-Bardón M, Pérez-Pertejo Y, Balaña-Fouce R, Reguera RM. Domínguez-Asenjo B, et al. Among authors: reguera rm. ACS Infect Dis. 2021 Aug 13;7(8):2390-2401. doi: 10.1021/acsinfecdis.1c00139. Epub 2021 Jun 11. ACS Infect Dis. 2021. PMID: 34114790
114 results